A mixed integer programming model for vaccine pricing within a group purchasing organization
Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average...
Uloženo v:
| Vydáno v: | Vaccine Ročník 42; číslo 8; s. 1892 - 1898 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
Elsevier Ltd
19.03.2024
Elsevier Limited |
| Témata: | |
| ISSN: | 0264-410X, 1873-2518, 1873-2518 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated.
We modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers’ ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers’ willingness to pay, subject to the constraint that the prices decrease in the buyers’ ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined.
The adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries.
This work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers.
This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. |
|---|---|
| AbstractList | Background:Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated.Methods:We modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers’ ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers’ willingness to pay, subject to the constraint that the prices decrease in the buyers’ ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined.Results:The adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries.Conclusions:This work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers.Funding:This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. AbstractBackground:Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated. Methods:We modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers’ ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers’ willingness to pay, subject to the constraint that the prices decrease in the buyers’ ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined. Results:The adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries. Conclusions:This work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers. Funding:This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated.BACKGROUNDSetting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated.We modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers' ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers' willingness to pay, subject to the constraint that the prices decrease in the buyers' ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined.METHODSWe modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers' ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers' willingness to pay, subject to the constraint that the prices decrease in the buyers' ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined.The adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries.RESULTSThe adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries.This work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers.CONCLUSIONSThis work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers.This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines.FUNDINGThis research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated. We modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers’ ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers’ willingness to pay, subject to the constraint that the prices decrease in the buyers’ ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined. The adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries. This work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers. This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different populations. When a group of buyers (e.g., countries) combine their purchasing power (e.g., via a group purchasing organization), the average procurement price decreases in the total volume. Decisions about what price to then charge to each member in a group are particularly challenging, considering the disparities in their respective ability and willingness to pay. Tiered pricing can be an effective way to set prices for a group of buyers, but its performance needs to be quantified and evaluated. We modeled the decision of setting prices of a medical product (for example, a vaccine) for a group of buyers using a mixed integer programming model, considering the buyers’ ability and willingness to pay. The objective is to minimize the unit price disparity adjusted by the buyers’ willingness to pay, subject to the constraint that the prices decrease in the buyers’ ability to pay. We also developed an analogous subsidy allocation model that applies if the group receives philanthropic donations to support procurement. The models were illustrated with two case studies based on the Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi, the Vaccine Alliance and Pan American Health Organization, and the performances of uniform, tiered, and differentiated pricing schemes were examined. The adjusted unit price disparity is non-increasing in the number of price tiers allowed. The biggest decrease in the adjusted price disparity occurs when switching to two-tier pricing from uniform pricing. Tiered pricing performs better in the Gavi group compared to the PAHO group, in part because the ability to pay and willingness to pay have a higher degree of rank correlation within the former group of countries. This work provides a model for price-setting (subsidy allocation) decisions for a group of buyers and provides a quantitative comparison of different pricing schemes. The results of the case studies suggest that the performance of tiered pricing depends on various factors, including the disparities in the ability and willingness to pay across the buyers. This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. |
| Author | Toktay, L. Beril Keskinocak, Pinar Orenstein, Walter A. Yu, Zhuoting |
| Author_xml | – sequence: 1 givenname: Zhuoting surname: Yu fullname: Yu, Zhuoting organization: H. Milton Stewart School of Industrial and Systems Engineering, Georgia Tech, 755 Ferst Drive NW, Atlanta, GA 30332, United States of America – sequence: 2 givenname: Pinar orcidid: 0000-0003-2686-546X surname: Keskinocak fullname: Keskinocak, Pinar email: pinar@isye.gatech.edu organization: H. Milton Stewart School of Industrial and Systems Engineering, Georgia Tech, 755 Ferst Drive NW, Atlanta, GA 30332, United States of America – sequence: 3 givenname: Walter A. orcidid: 0000-0003-3932-8209 surname: Orenstein fullname: Orenstein, Walter A. organization: Emory University, 954 Gatewood Road, Atlanta, GA 30329, United States of America – sequence: 4 givenname: L. Beril orcidid: 0000-0001-7446-8253 surname: Toktay fullname: Toktay, L. Beril organization: Scheller College of Business, Georgia Tech, 800 West Peachtree ST NW, Atlanta, GA 30308, United States of America |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37977944$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEUhoNU7Lb6E5QBb7yZNZ-TCaJSSv2AghcqeCGETObMNutMsk1mauuvN-OuvViQ9Spw3ve8OXlOTtCRDx4QekrwkmBSvVwvb4y1zsOSYspybYk5foAWpJaspILUR2iBacVLTvC3Y3SS0hpjLBhRj9Axk0pKxfkCfT8rBncLbeH8CCuIxSaGVTTD4PyqGEILfdGFWOzuyqqzs_LTjVfOF6ZYxTBtis0U7ZVJsxLiynj3y4wu-MfoYWf6BE925yn6-u7iy_mH8vLT-4_nZ5elFUyMJTDRQM2FANwqDriyTQcNUxgr1lAucWc6nCWoK6EkF1xJ1gI3FTOiMsDZKXqxzc3DX0-QRj24ZKHvjYcwJc2I4KSqSHXYSmtFpKgzpmx9vmddhyn6_BBNlagkUbWcA5_tXFMzQKszocHEO_0XcTaIrcHGkFKE7t5CsJ5Xqdd6h1fPq5zLeZW579Ven3XjH6xjNK4_2P122w2Z-42DqJN14C20LoIddRvcwYQ3ewm2d95Z0_-AO0j3LIhOVGP9ef5s81-jDBNK2czv9b8D_mOA3-HP5hA |
| CitedBy_id | crossref_primary_10_1016_j_ijpe_2025_109705 |
| Cites_doi | 10.1046/j.1365-3156.2001.00801.x 10.1186/1744-8603-7-39 10.1287/msom.1110.0355 10.1016/S0140-6736(14)61483-5 10.1016/j.vaccine.2015.09.033 10.1136/bmjgh-2020-004823 10.1002/nav.20305 10.12688/gatesopenres.13110.3 10.1016/S0140-6736(02)08911-0 10.1111/j.1937-5956.2010.01121.x 10.1016/S1473-3099(04)01255-1 10.1002/hec.3013 10.1016/S0140-6736(13)62424-1 10.2471/BLT.08.058925 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier Ltd Elsevier Ltd Copyright © 2023 Elsevier Ltd. All rights reserved. 2023. Elsevier Ltd |
| Copyright_xml | – notice: 2023 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2023 Elsevier Ltd. All rights reserved. – notice: 2023. Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2023.10.040 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Proquest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Consumer Health Database ProQuest Health & Medical Collection ProQuest Health Management Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Research Library Prep MEDLINE - Academic AGRICOLA MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 1898 |
| ExternalDocumentID | 37977944 10_1016_j_vaccine_2023_10_040 S0264410X23012239 1_s2_0_S0264410X23012239 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Georgia |
| GeographicLocations_xml | – name: Georgia |
| GrantInformation | This research has been supported in part by the Center for Health and Humanitarian Systems, the William W. George endowment, and the following benefactors at Georgia Tech: Andrea Laliberte, Richard Rick E. and Charlene Zalesky, and Claudia and Paul Raines. |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACMHX ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADSLC AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGWPP AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- ~HD .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK 9DU AAYXX AFFHD AGQPQ CITATION AGCQF CGR CUY CVF ECM EIF NPM PUEGO 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c535t-e35be8455e0d94e06cbfeb390093b2470faf00d9e86597454973de4a63a56ae43 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001236922900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Thu Oct 02 21:41:47 EDT 2025 Sat Nov 01 14:50:05 EDT 2025 Tue Nov 18 09:41:11 EST 2025 Sat Aug 30 01:59:06 EDT 2025 Tue Nov 18 20:54:11 EST 2025 Sat Nov 29 02:26:35 EST 2025 Sat May 11 15:33:21 EDT 2024 Tue Feb 25 20:03:34 EST 2025 Tue Oct 14 19:30:28 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Vaccine procurement Uniform pricing Equity in pricing Tiered pricing Group purchasing |
| Language | English |
| License | Copyright © 2023 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c535t-e35be8455e0d94e06cbfeb390093b2470faf00d9e86597454973de4a63a56ae43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2686-546X 0000-0001-7446-8253 0000-0003-3932-8209 |
| PMID | 37977944 |
| PQID | 2956719874 |
| PQPubID | 105530 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_3154166164 proquest_miscellaneous_2891758319 proquest_journals_2956719874 pubmed_primary_37977944 crossref_primary_10_1016_j_vaccine_2023_10_040 crossref_citationtrail_10_1016_j_vaccine_2023_10_040 elsevier_sciencedirect_doi_10_1016_j_vaccine_2023_10_040 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X23012239 elsevier_clinicalkey_doi_10_1016_j_vaccine_2023_10_040 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-19 |
| PublicationDateYYYYMMDD | 2024-03-19 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | (b8) 2021 Chalkidou, Claxton, Silverman, Yadav (b11) 2020; 4 (b28) 2021 Pérez-Casas, Herranz, Ford (b20) 2001; 6 Hinman, McKinlay (b5) 2015; 33 Keskinocak, Savaşaneril (b15) 2008; 55 (b18) 2021 (b1) 2023 Waning, Kaplan, King, Lawrence, Leufkens, Fox (b14) 2009; 87 Danzon, Mulcahy, Towse (b29) 2015; 24 Hu, Schwarz (b12) 2011; 20 (b6) 2022 Hu, Schwarz, Uhan (b13) 2012; 14 (b26) 2022 Plahte (b16) 2005; 5 (b3) 2021 Yadav (b4) 2010 (b22) 2022 World Health Organization (b19) 2022 Castillo-Zunino, Keskinocak, Nazzal, Freeman (b27) 2021; 6 (b2) 2023 Lopert, Lang, Hill, Henry (b21) 2002; 359 Balasegaram (b24) 2014; 384 (b30) 2023 (b9) 2021 Moon, Jambert, Childs, von Schoen-Angerer (b10) 2011; 7 (b25) 2022 Berkley (b23) 2014; 383 (b17) 2021 (b7) 2021 Keskinocak (10.1016/j.vaccine.2023.10.040_b15) 2008; 55 Yadav (10.1016/j.vaccine.2023.10.040_b4) 2010 Plahte (10.1016/j.vaccine.2023.10.040_b16) 2005; 5 Hu (10.1016/j.vaccine.2023.10.040_b13) 2012; 14 Pérez-Casas (10.1016/j.vaccine.2023.10.040_b20) 2001; 6 Castillo-Zunino (10.1016/j.vaccine.2023.10.040_b27) 2021; 6 Hinman (10.1016/j.vaccine.2023.10.040_b5) 2015; 33 (10.1016/j.vaccine.2023.10.040_b9) 2021 Hu (10.1016/j.vaccine.2023.10.040_b12) 2011; 20 Danzon (10.1016/j.vaccine.2023.10.040_b29) 2015; 24 Waning (10.1016/j.vaccine.2023.10.040_b14) 2009; 87 (10.1016/j.vaccine.2023.10.040_b2) 2023 (10.1016/j.vaccine.2023.10.040_b7) 2021 (10.1016/j.vaccine.2023.10.040_b18) 2021 (10.1016/j.vaccine.2023.10.040_b26) 2022 (10.1016/j.vaccine.2023.10.040_b28) 2021 Lopert (10.1016/j.vaccine.2023.10.040_b21) 2002; 359 Chalkidou (10.1016/j.vaccine.2023.10.040_b11) 2020; 4 Balasegaram (10.1016/j.vaccine.2023.10.040_b24) 2014; 384 (10.1016/j.vaccine.2023.10.040_b3) 2021 (10.1016/j.vaccine.2023.10.040_b25) 2022 World Health Organization (10.1016/j.vaccine.2023.10.040_b19) 2022 (10.1016/j.vaccine.2023.10.040_b30) 2023 (10.1016/j.vaccine.2023.10.040_b8) 2021 (10.1016/j.vaccine.2023.10.040_b22) 2022 Berkley (10.1016/j.vaccine.2023.10.040_b23) 2014; 383 Moon (10.1016/j.vaccine.2023.10.040_b10) 2011; 7 (10.1016/j.vaccine.2023.10.040_b1) 2023 (10.1016/j.vaccine.2023.10.040_b6) 2022 (10.1016/j.vaccine.2023.10.040_b17) 2021 |
| References_xml | – volume: 7 start-page: 39 year: 2011 ident: b10 article-title: A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries publication-title: Glob Health – volume: 14 start-page: 7 year: 2012 end-page: 23 ident: b13 article-title: The impact of group purchasing organizations on healthcare-product supply chains publication-title: Manuf Serv Oper Manag – year: 2021 ident: b7 article-title: Immunization, vaccines and biologicals - Immunization financing indicators – year: 2022 ident: b22 article-title: GAVI approach creates tiered pricing for vaccines – year: 2021 ident: b17 article-title: (Mis)Understanding Overhead – year: 2021 ident: b3 article-title: 2019 Global vaccine market report – volume: 384 start-page: 852 year: 2014 ident: b24 article-title: Is tiered pricing the way for vaccines? publication-title: Lancet – volume: 55 start-page: 516 year: 2008 end-page: 540 ident: b15 article-title: Collaborative procurement among competing buyers publication-title: Nav Res Logist – volume: 6 year: 2021 ident: b27 article-title: Health spending and vaccination coverage in low-income countries publication-title: BMJ Global Health – year: 2022 ident: b6 article-title: GNI per capita, PPP (current international $) – volume: 5 start-page: 58 year: 2005 end-page: 63 ident: b16 article-title: Tiered pricing of vaccines: a win-win-win situation, not a subsidy publication-title: Lancet Infect Dis – volume: 33 start-page: D72 year: 2015 end-page: D77 ident: b5 article-title: Immunization equity publication-title: Vaccine – volume: 6 start-page: 960 year: 2001 end-page: 964 ident: b20 article-title: Pricing of drugs and donations: options for sustainable equity pricing publication-title: Trop Med Int Health – year: 2022 ident: b25 article-title: Global vaccine differential pricing approach – year: 2023 ident: b1 article-title: The 17 sustainable development goals, United Nations – year: 2023 ident: b30 article-title: PAHO revolving fund – year: 2023 ident: b2 article-title: Operating procedures of the PAHO revolving fund for the purchase of vaccines, syringes, and other related supplies – year: 2021 ident: b8 article-title: PAHO vaccine prices for year 2020 – year: 2022 ident: b26 article-title: GSK Public policy positions - Tiered pricing and vaccines – volume: 359 start-page: 2105 year: 2002 end-page: 2107 ident: b21 article-title: Differential pricing of drugs: a role for cost-effectiveness analysis? publication-title: Lancet – volume: 24 start-page: 238 year: 2015 end-page: 252 ident: b29 article-title: Pharmaceutical pricing in emerging markets: Effects of income, competition, and procurement publication-title: Health Econ – volume: 383 start-page: 2265 year: 2014 end-page: 2267 ident: b23 article-title: Improving access to vaccines through tiered pricing publication-title: Lancet – volume: 20 start-page: 1 year: 2011 end-page: 15 ident: b12 article-title: Controversial role of GPOs in healthcare-product supply chains publication-title: Prod Oper Manage – year: 2021 ident: b9 article-title: Co-financing policy – year: 2021 ident: b28 article-title: Immunization financing indicators – year: 2010 ident: b4 article-title: Differential pricing for pharmaceuticals: Review of current knowledge, new findings and ideas for action. – volume: 87 start-page: 520 year: 2009 end-page: 528 ident: b14 article-title: Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases publication-title: Bull World Health Organ – volume: 4 start-page: 16 year: 2020 ident: b11 article-title: Value-based tiered pricing for universal health coverage: an idea worth revisiting publication-title: Gates Open Res – year: 2022 ident: b19 article-title: Vaccines and immunization – year: 2021 ident: b18 article-title: Eligibility and transition policy – volume: 6 start-page: 960 issue: 11 year: 2001 ident: 10.1016/j.vaccine.2023.10.040_b20 article-title: Pricing of drugs and donations: options for sustainable equity pricing publication-title: Trop Med Int Health doi: 10.1046/j.1365-3156.2001.00801.x – year: 2022 ident: 10.1016/j.vaccine.2023.10.040_b25 – year: 2022 ident: 10.1016/j.vaccine.2023.10.040_b19 – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b3 – year: 2023 ident: 10.1016/j.vaccine.2023.10.040_b30 – volume: 7 start-page: 39 issue: 1 year: 2011 ident: 10.1016/j.vaccine.2023.10.040_b10 article-title: A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries publication-title: Glob Health doi: 10.1186/1744-8603-7-39 – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b9 – volume: 14 start-page: 7 issue: 1 year: 2012 ident: 10.1016/j.vaccine.2023.10.040_b13 article-title: The impact of group purchasing organizations on healthcare-product supply chains publication-title: Manuf Serv Oper Manag doi: 10.1287/msom.1110.0355 – volume: 384 start-page: 852 issue: 9946 year: 2014 ident: 10.1016/j.vaccine.2023.10.040_b24 article-title: Is tiered pricing the way for vaccines? publication-title: Lancet doi: 10.1016/S0140-6736(14)61483-5 – year: 2022 ident: 10.1016/j.vaccine.2023.10.040_b26 – volume: 33 start-page: D72 issn: 0264-410X year: 2015 ident: 10.1016/j.vaccine.2023.10.040_b5 article-title: Immunization equity publication-title: Vaccine doi: 10.1016/j.vaccine.2015.09.033 – volume: 6 issue: 5 year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b27 article-title: Health spending and vaccination coverage in low-income countries publication-title: BMJ Global Health doi: 10.1136/bmjgh-2020-004823 – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b28 – volume: 55 start-page: 516 issue: 6 year: 2008 ident: 10.1016/j.vaccine.2023.10.040_b15 article-title: Collaborative procurement among competing buyers publication-title: Nav Res Logist doi: 10.1002/nav.20305 – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b8 – volume: 4 start-page: 16 year: 2020 ident: 10.1016/j.vaccine.2023.10.040_b11 article-title: Value-based tiered pricing for universal health coverage: an idea worth revisiting publication-title: Gates Open Res doi: 10.12688/gatesopenres.13110.3 – year: 2022 ident: 10.1016/j.vaccine.2023.10.040_b6 – volume: 359 start-page: 2105 issue: 9323 year: 2002 ident: 10.1016/j.vaccine.2023.10.040_b21 article-title: Differential pricing of drugs: a role for cost-effectiveness analysis? publication-title: Lancet doi: 10.1016/S0140-6736(02)08911-0 – year: 2022 ident: 10.1016/j.vaccine.2023.10.040_b22 – volume: 20 start-page: 1 issue: 1 year: 2011 ident: 10.1016/j.vaccine.2023.10.040_b12 article-title: Controversial role of GPOs in healthcare-product supply chains publication-title: Prod Oper Manage doi: 10.1111/j.1937-5956.2010.01121.x – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b17 – year: 2010 ident: 10.1016/j.vaccine.2023.10.040_b4 – year: 2023 ident: 10.1016/j.vaccine.2023.10.040_b1 – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b7 – volume: 5 start-page: 58 issue: 1 year: 2005 ident: 10.1016/j.vaccine.2023.10.040_b16 article-title: Tiered pricing of vaccines: a win-win-win situation, not a subsidy publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(04)01255-1 – volume: 24 start-page: 238 issue: 2 year: 2015 ident: 10.1016/j.vaccine.2023.10.040_b29 article-title: Pharmaceutical pricing in emerging markets: Effects of income, competition, and procurement publication-title: Health Econ doi: 10.1002/hec.3013 – volume: 383 start-page: 2265 issue: 9936 year: 2014 ident: 10.1016/j.vaccine.2023.10.040_b23 article-title: Improving access to vaccines through tiered pricing publication-title: Lancet doi: 10.1016/S0140-6736(13)62424-1 – volume: 87 start-page: 520 issue: 7 year: 2009 ident: 10.1016/j.vaccine.2023.10.040_b14 article-title: Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases publication-title: Bull World Health Organ doi: 10.2471/BLT.08.058925 – year: 2023 ident: 10.1016/j.vaccine.2023.10.040_b2 – year: 2021 ident: 10.1016/j.vaccine.2023.10.040_b18 |
| SSID | ssj0005319 |
| Score | 2.441775 |
| Snippet | Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across different... AbstractBackground:Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health... Background:Setting prices for life-saving medical or pharmaceutical products needs to consider multiple factors, e.g., affordability and health outcomes across... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1892 |
| SubjectTerms | affordability Allergy and Immunology Bacillus Calmette-Guerin vaccine BCG BCG Vaccine Case studies Costs and Cost Analysis Decisions Equity in pricing Georgia Group Purchasing Integer programming Melica Mixed integer Mycobacterium bovis BCG Prices Pricing Procurement Purchasing Subsidies Tiered pricing Uniform pricing Vaccine procurement Vaccines Willingness to pay |
| Title | A mixed integer programming model for vaccine pricing within a group purchasing organization |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X23012239 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X23012239 https://dx.doi.org/10.1016/j.vaccine.2023.10.040 https://www.ncbi.nlm.nih.gov/pubmed/37977944 https://www.proquest.com/docview/2956719874 https://www.proquest.com/docview/2891758319 https://www.proquest.com/docview/3154166164 |
| Volume | 42 |
| WOSCitedRecordID | wos001236922900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20211217 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIEXJ dateStart: 20211208 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M7P dateStart: 20020101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & allied health premium. customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Consumer Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0R dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health Management customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYBogXBmVAYVRGQntaOid2PvyEuqkTIK1Uo0x5QLISx0GdWFqabmL_PXeO0_KwMSRerlLsa5zYOf_ufB-EvMtLKbVhzJOFNp6IIu3lAQdidBaajGGSMltsIh6NkjSVY2dwq51bZSsTraAuZhpt5AcBAPkYNWTxfv7Tw6pReLrqSmhskC3MksCt69547eLBbWEPUDOEJ3yWriN4Ds77V5nGo-s-1g_vo4MX2j9u3ptuw552Dzre_t_RPyGPHfqkg2a5PCX3TNUhD5p6lNcd8vDEnbR3yN64yWl9vU8n6xCtep_u0fE62zXwdM7QocZG9dKW_Rn5NqAX01-moDYdhVlQ5wd2ATsltdV3KKBl6t4OtCLfd4pW4WlFM2qDTegcK1VlaM2gsz9iRnfI1-Ph5OiD5wo5eDrk4dIzPMxNIsLQsEIKwyKdl6DESzSn5IGIWZmVDJpMEqF-AyprzAsjsohnYZQZwZ-TzWpWmZeE5oBvJIA-WzW7KBPoY6QJIq5jlpRB1CWinUKlXZZzLLbxQ7XubOfKPZvCmcfLMPNd0l-xzZs0H3cxRO36UG0MK0hdBRvRXYzxTYymdrKjVr6qA8XUF2axKktBSfQBxMkuSVacDh41sOdfbrrbLku1us96TXbJ21UzSBc8MsoqM7uEPgmo82EC39HtfTigcB9gXgT_86L5PFbvkMegX0ghXv19AK_JIxitQN8-X-6SzeXi0rwh9_XVclovemQjPj1DmsaWJkCTI79HtgYfh-kn-D0cjsancPWENXSCNPjcs-LgN-p6Xss |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VAoULj_AKFDAS9NRNnV3vwweEKqBq1SaKRKhyQDK7Xm-Vim5CNi3kT_EbmfE-wqGlXHrgkkPs2Yd3xv7GnpkP4HWSSakN545MtXFEEGgncT38MTr2TcypSJklmwj7_Wg0koMV-FXnwlBYZT0n2ok6nWjaI99yEciH5CGLd9PvDrFG0elqTaFRqsW-WfxAl614u_cBv-8b1935OHy_61SsAo72PX_uGM9PTCR83_BUCsMDnWToUUry7RNXhDyLM45NJgoIbKP_FHqpEXHgxX4QG-Hhda_BdaqrRyGEPT5chpR4lkgE3RrhiC4fLTOGto47Z7Gmo_IO8ZV3KKCM9lvOXwsvwrp2zdu5-7-N1j24U6Frtl2aw31YMXkLbpZ8m4sWrPWqSIIWbAzKmt2LTTZcpqAVm2yDDZbVvFGmdUgBQzZrmdXiD-DLNjsZ_zQps-U2zIxVcW4niASYZRdi6A2w6mtgK8kdMdr1HucsZjaZhk2JiSum3Ro2-SMn9iF8vpJBegSr-SQ3T4AliN8kglrLCp5mEfYx0riBp0MeZW7QBlGrjNJVFXciE_mm6nC9Y1W9myJNo79R09rQacSmZRmTywSCWh9VnaOLq4rChfYywfA8QVNUc2OhuqpwFVefuMXifIROcBdBqmxD1EhW8K-Edf9y0_XaDFRzn6UNtOFV04yzJx2JxbmZnGKfSCJ-jtBuL-7joZfRRRgb4HUel-bYjKEXov8khXj69wd4Cbd2h70DdbDX338Gt_HJBcUxduU6rM5np-Y53NBn83Exe2EnFAZfr9omfwN7MLFl |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VAhUXHgFKoICRoKdu4qy9Dx8QqloiqkIUiYJyqGR2vV6Uqk1CNi3kr_HrmPHuJj20lEsPXHKIPfvwztjf2DPzAbxOc6WM5dxTmbGeDEPjpb7AH2uSwCacipQ5somo14sHA9Vfgd91LgyFVdZzopuos7GhPfK2j0A-Ig9ZtvMqLKK_2303-eERgxSdtNZ0GqWK7Nv5T3Tfird7u_it3_h-9_3BzgevYhjwTCCCmWdFkNpYBoHlmZKWhybN0btU5Oenvox4nuQcm2wcEvBGXyoSmZVJKJIgTKwUeN0bcDMSqMWUpb5zLrxEOFIRdHGkJzt8sMweah-1zhJDx-Yt4i5vUXAZ7b1cvC5ehnvd-te99z-P3H24W6Futl2ayQNYsaMG3C55OOcNWPtURRg0YLNf1vKeb7GDZWpascU2WX9Z5RtlGl8pkMhlM7Na_CEcbrOT4S-bMVeGw05ZFf92ggiBOdYhhl4Cq74MtpLcd0a74cMRS5hLsmETYuhKaBeHjc_lyj6CL9cySI9hdTQe2SfAUsR1CsGuYwvP8hj7WGX9UJiIx7kfNkHW6qNNVd2dSEaOdR3Gd6Srd9OkdfQ3al0TWguxSVne5CqBsNZNXefu4mqjcQG-SjC6SNAW1ZxZ6I4ufM31Z-4wOh-gc9xB8KqaEC8kK1hYwr1_uelGbRJ6cZ-lPTTh1aIZZ1U6KktGdnyKfWKFuDpGG768j0Dvo4PwNsTrrJemuRhDEaFfpaR8-vcHeAlraIr6415v_xncwQeXFN7YURuwOpue2udwy5zNhsX0hZtbGHy7bpP8A77LueM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+mixed+integer+programming+model+for+vaccine+pricing+within+a+group+purchasing+organization&rft.jtitle=Vaccine&rft.au=Yu%2C+Zhuoting&rft.au=Keskinocak%2C+Pinar&rft.au=Orenstein%2C+Walter+A&rft.au=Toktay%2C+L.+Beril&rft.date=2024-03-19&rft.issn=0264-410X&rft_id=info:doi/10.1016%2Fj.vaccine.2023.10.040&rft.externalDBID=ECK1-s2.0-S0264410X23012239&rft.externalDocID=1_s2_0_S0264410X23012239 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |